Evidence map›Paper›PMID 41592291›Full record

ArticleBlood2026

Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.

Viktoria Blumenberg, Filippo Birocchi, Angela Shih, Giulia Escobar, Adele Mucci, Alexander Armstrong, Diana Cirstea, Deshea L Harris, David J Bozym, Benjamin R Puliafito and 31 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors.

Viktoria BlumenbergCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-1379-0876
Filippo BirocchiCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-5214-233X
Angela ShihDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-8945-5997
Giulia EscobarCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0001-9177-0251
Adele MucciCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-1532-4414
Alexander ArmstrongCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0009-0003-6957-9903
Diana CirsteaHematology and Oncology Division, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-5719-581X
Deshea L HarrisCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
David J BozymHematology and Oncology Division, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Benjamin R PuliafitoCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-3972-6362
Richard NewcombCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Tejaswini M DhawaleCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-0163-2061
Patrick C JohnsonCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-3943-6608
Areej El-JawahriCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Richard JeffreyCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Alexis L BarselauCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Alex LiCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Estelle Emmanuel-AlejandroCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Daniella CookCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Kevin LindellCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Samantha O LukCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Ryan ChaffeeCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0009-0005-2124-0702
Andrew J YeeCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-3623-7491
Andrew BranaganCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-3868-9267
Noopur RajeCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Charlotte E GrahamComprehensive Cancer Centre, King's College London, London, United Kingdom.
Sarah P HammondHematology and Oncology Division, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Frederic D BushmanDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Aoife M RocheDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Shantan ReddyDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Alexander G McFarlandDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Yi-Bin ChenCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-9554-1058
Bryan D ChoiCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Christopher W MountDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Michael DouganDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0001-9266-2009
Valentina NardiDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-0486-416X
Aliyah R SohaniDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-6307-4854
Kathleen M E GallagherCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0009-0004-4818-2082
Marcela V MausCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-7578-0393
Matthew J FrigaultCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-6774-5694
Mark B LeickCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-3111-0221

Funding

Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucelR01CA252940 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MAUS, MARCELA VALDERRAMA · 2020 to 2024
$3.4M
Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinomaK08CA289948 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Mark Leick · 2024 to 2026
$893k
NCI NIH HHS K08 CA289948NCI NIH HHS R01 CA252940
6 · The paper itself

Abstract

abstractIntractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell-associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.

Indexed as

B-Cell Maturation AntigenDiarrheaImmunotherapy, AdoptivePyrazolesReceptors, Chimeric AntigenAgedFemaleHumansMaleMiddle AgedNitrilesPyrimidinesB-Cell Maturation AntigenNitrilesPyrazolesPyrimidinesReceptors, Chimeric Antigenruxolitinib

Identifiers

PMID41592291
PMCPMC13235656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.